Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Biomolecules ; 13(2)2023 02 08.
Article in English | MEDLINE | ID: mdl-36830690

ABSTRACT

Both cardiovascular disease and cancer continue to be causes of morbidity and mortality all over the world. Preventing and treating heart disease in patients undergoing cancer treatment remain an important and ongoing challenge for improving the lives of cancer patients, but also for their survival. Despite ongoing efforts to improve patient survival, minimal advances have been made in the early detection of cardiovascular disease in patients suffering from cancer. Understanding the communication between cancer and cardiovascular disease can be based on a deeper knowledge of the molecular mechanisms that define the profile of the bilateral network and establish disease-specific biomarkers and therapeutic targets. The role of exosomes, microvesicles, and apoptotic bodies, together defined as extracellular vesicles (EVs), in cross talk between cardiovascular disease and cancer is in an incipient form of research. Here, we will discuss the preclinical evidence on the bilateral connection between cancer and cardiovascular disease (especially early cardiac changes) through some specific mediators such as EVs. Investigating EV-based biomarkers and therapies may uncover the responsible mechanisms, detect the early stages of cardiovascular damage and elucidate novel therapeutic approaches. The ultimate goal is to reduce the burden of cardiovascular diseases by improving the standard of care in oncological patients treated with anticancer drugs or radiotherapy.


Subject(s)
Cardiovascular Diseases , Exosomes , Extracellular Vesicles , Neoplasms , Humans , Biomarkers
2.
J Clin Med ; 11(11)2022 May 31.
Article in English | MEDLINE | ID: mdl-35683521

ABSTRACT

Hypertensive emergencies (HE) represent high cardiovascular risk situations defined by a severe increase in blood pressure (BP) associated with acute, hypertension mediated organ damage (A-HMOD) to the heart, brain, retina, kidneys, and large arteries. Blood pressure values alone do not accurately predict the presence of HE; therefore, the search for A-HMOD should be the first step in the management of acute severe hypertension. A rapid therapeutic intervention is mandatory in order to limit and promote regression of end-organ damage, minimize the risk of complications, and improve patient outcomes. Drug therapy for HE, target BP, and the speed of BP decrease are all dictated by the type of A-HMOD, specific drug pharmacokinetics, adverse drug effects, and comorbidities. Therefore, a tailored approach is warranted. However, there is currently a lack of solid evidence for the appropriate treatment strategies for most HE. This article reviews current pharmacological strategies while providing a stepwise, evidence based approach for the management of HE.

3.
Pharmaceutics ; 13(5)2021 May 13.
Article in English | MEDLINE | ID: mdl-34068168

ABSTRACT

Resistant hypertension (R-HTN) implies a higher mortality and morbidity compared to non-R-HTN due to increased cardiovascular risk and associated adverse outcomes-greater risk of developing chronic kidney disease, heart failure, stroke and myocardial infarction. R-HTN is considered when failing to lower blood pressure below 140/90 mmHg despite adequate lifestyle measures and optimal treatment with at least three medications, including a diuretic, and usually a blocker of the renin-angiotensin system and a calcium channel blocker, at maximally tolerated doses. Hereby, we discuss the diagnostic and therapeutic approach to a better management of R-HTN. Excluding pseudoresistance, secondary hypertension, white-coat hypertension and medication non-adherence is an important step when diagnosing R-HTN. Most recently different phenotypes associated to R-HTN have been described, specifically refractory and controlled R-HTN and masked uncontrolled hypertension. Optimizing the three-drug regimen, including the diuretic treatment, adding a mineralocorticoid receptor antagonist as the fourth drug, a ß-blocker as the fifth drug and an α1-blocker or a peripheral vasodilator as a final option when failing to achieve target blood pressure values are current recommendations regarding the correct management of R-HTN.

4.
Rom J Morphol Embryol ; 61(3): 923-927, 2020.
Article in English | MEDLINE | ID: mdl-33817735

ABSTRACT

Right ventricular (RV) myxoma is a very rare finding. Its differential diagnosis includes cardiac thrombus, and its risk of life-threatening complications mandates early diagnosis followed by surgical resection. We report the case of a patient with an incidental RV mass and a difficult differential diagnosis. A 66-year-old woman, first assessed in neurosurgery due to a lumbar herniated disc, was referred to cardiology for examination before proceeding to surgery. She complained of dyspnea on exertion present for the last few months and reported no fainting or syncope. Clinical examination showed intermittent pulmonary systolic murmur. Transthoracic echocardiography revealed an oval-shaped sessile mobile mass (42∕18 mm) attached to the anterior RV wall. Computed tomography confirmed the presence of a RV mass with lower attenuation than the myocardium and extension towards the pulmonary trunk, without other abdominal or pulmonary masses that would suggest a thrombus. Cardiac magnetic resonance imaging described an ovoid mass (47∕16 mm) in the right ventricle, "clinging" to the apical trabeculae, swinging during the cardiac cycle, causing partial obstruction of the pulmonary valve during systole. The patient underwent surgical resection of the tumor. Macroscopic specimen showed a translucent polypoid mass with hemorrhagic areas. Microscopy confirmed the diagnosis of RV myxoma. The case illustrates the difficulty of establishing the correct etiological diagnosis of a cardiac mass, especially when located in the right ventricle. Multimodality imaging remains the cornerstone of noninvasive tissue characterization of cardiac masses, still requiring histopathological confirmation, particularly in the setting of conflicting imaging results.


Subject(s)
Heart Neoplasms , Myxoma , Aged , Echocardiography , Female , Heart Neoplasms/diagnostic imaging , Heart Ventricles/diagnostic imaging , Humans , Magnetic Resonance Imaging , Myxoma/diagnostic imaging
5.
Maedica (Bucur) ; 13(2): 112-119, 2018 Jun.
Article in English | MEDLINE | ID: mdl-30069237

ABSTRACT

BACKGROUND: The largest European Roma community resides in Romania, but there is still little published data on cardiovascular (CV) risk factors and disease in this group. This study addresses the prevalence of arterial hypertension, associated CV disease risk, and target organ damage (TOD) in a Roma community from Bucharest, Romania. METHODS: This is a cross-sectional community-based participatory research to assess for CV risk factors, TOD and CV disease, including 806 Roma ethnics (18-83 years) integrated in the local community, 36.16% males. Evaluation included physical examination with blood pressure, pulse wave velocity and anklebrachial measurements, laboratory tests, ECG, echocardiography and fundoscopy. RESULTS: Prevalence of hypertension was 33.62%, awareness 76.38%, higher in females (p>0.01), and control rate 44.39%. Compared to age-matched normotensives, hypertensives had more left ventricle hypertrophy and more frequently increased pulse pressure. Differences in TOD were attenuated between newly and previously diagnosed, controlled and uncontrolled, hypertensives. Cardiovascular disease was almost absent in normotensives. Ten-year risk for fatal CV disease followed an increasing trend from normotension to long standing hypertension. CONCLUSION: This is the first dedicated study to thoroughly assess TOD and risk for fatal CV disease in a Romanian Roma population. Hypertension was less prevalent than in the general population, with similar awareness, possibly as a consequence of integration in the surrounding community. Fatal CV disease risk followed the trend of increasing prevalence of risk factors, and hypertension played an important role in its modulation.

6.
Rom J Intern Med ; 56(3): 193-202, 2018 Sep 01.
Article in English | MEDLINE | ID: mdl-29561733

ABSTRACT

BACKGROUND: The Roma population has a high prevalence of cardiovascular risk factors, higher mortality, and shorter life expectancy. It is found in the largest number in Romania, but published data are still scarce here. We studied cardiovascular risk factors and disease along with target organ damage on a population of Roma inhabitants from Bucharest, Romania. METHODS: This cross-sectional study enrolled 806 Roma subjects (18-83 years), in a community-based participatory research manner. Demographics included anthropometric data, a questionnaire on social status, education, medical history, and health deleterious behaviors. Medical evaluation included clinical examination, blood pressure, ankle-brachial index, pulse wave velocity measurements, blood tests (complete blood count, lipid profile, glucose, creatinine, uric acid), dip-stick microalbuminuria, dilated fundoscopy, ECG, and echocardiography. RESULTS: Prevalence of all cardiovascular risk factors was high, peaking in abnormal lipid metabolism (82.13%), heavy smoking (63.02% including ex-smokers) and obesity (50.99%). The first and the latter were actually similar to the general population in Romania. Almost half of subjects were at high or very high risk for fatal cardiovascular disease. CONCLUSIONS: The study shows that the Roma population in a more affluent region in Romania shares a similarly high cardiovascular burden to their surrounding community.


Subject(s)
Cardiovascular Diseases/epidemiology , Roma/statistics & numerical data , Adolescent , Adult , Aged , Aged, 80 and over , Cross-Sectional Studies , Female , Humans , Male , Middle Aged , Risk Factors , Romania/epidemiology , Young Adult
7.
Rom J Morphol Embryol ; 58(3): 983-988, 2017.
Article in English | MEDLINE | ID: mdl-29250678

ABSTRACT

Meningiomas are among the most commonly encountered tumors of the central nervous system, being more frequent in females. We present the case of a dyslipidemic male patient, previously diagnosed with coronary artery disease for which he previously underwent percutaneous coronary intervention with the placement of two bare metal stents on the left anterior descending artery. He was presented to the emergency department for atypical angina and a seven-day history of dizziness when switching from clino- to orthostatism, reduced visual acuity, diplopia and vomiting. Electrocardiogram (ECG), both at rest and exercise test were suggestive for myocardial ischemia. Echocardiography revealed myocardial hypokinesia in the territory of the right coronary artery and of the left descending artery, while coronarography showed insignificant intra-stent stenosis. Imaging techniques revealed a frontobasal extraneuraxial mass, creating a compressive effect on both middle cerebral arteries and on the optic chiasm as well as thickening of the dura mater adjacent to the mass. Endocrinology blood tests showed hypocortisolemia, hyperprolactinemia and low levels of free thyroxine (fT4), suggesting secondary combined pituitary hormone deficiency. The patient underwent surgery and total resection of the tumor was performed. Definite diagnosis - transitional meningioma - was obtained through histological examination and immunohistochemistry. The key feature of this case was the extra-cardiac cause of angina accompanied by ECG abnormalities in a patient with stable coronary heart disease, in whom the clinical presentation was secondary to blood pressure variations in the context of pituitary and adrenal deficiency.


Subject(s)
Meningioma/diagnosis , Pituitary Neoplasms/diagnosis , Aged , Humans , Male , Meningioma/pathology , Pituitary Neoplasms/pathology
8.
Maedica (Bucur) ; 11(2): 101-108, 2016 Jun.
Article in English | MEDLINE | ID: mdl-28461828

ABSTRACT

BACKGROUND: Blood pressure variability (BPV) has recently been associated with adverse cardiovascular (CV) events, endothelial dysfunction as well as both CV and non-CV morbidity and mortality. Different BPV indicators have been associated with increased CV risk. METHODS: We included 744 hypertensive patients referred to our clinic for uncontrolled arterial hypertension (HTN) between 2012 and 2014, with a minimum of 40 successful daytime and 8 successful nighttime readings on automatic blood pressure monitoring (ABPM Meditech-05 device, recordings at 15-20 minutes intervals during daytime and 20-30 minutes intervals during nighttime). Exclusion criteria were presence of secondary HTN, significant CV disease and estimated glomerular filtration rate <30 ml/min/1.73 m2. BPV was expressed as dipping pattern, BP load, SD of 24-hour mean BP, average weighted SD and average real variability (ARV). RESULTS: All patients were known hypertensives, however their average blood pressure (BP) values on 24-hour ABPM were below 135/85 mmHg. The average dipping was higher in dippers (p<0.01) and nighttime systolic BP (SBP) load was increased among the non-dippers group (p<0.01). Mean diastolic BP (DBP) was slightly increased in dippers vs. non-dippers (75.82 ± 10.28 mmHg vs. 71.42 ± 10.17 mmHg, p<0.01). Of the total of 407 dippers, 31.2% displayed an extreme dipping pattern, whereas 29.67% of the 337 non-dippers were risers. In our study, average SBP, daytime and nighttime SBP SD and ARV did not differ significantly between the two extreme groups, as opposed to classical indicators such as SBP load (p<0.01) and weighted SD (p 0.02). CONCLUSION: In the emergency hospital setting, hypertensive patients can have normal mean BP values, but still can display a very high variability and in most cases abnormal dipping profiles, requiring a strictly controlled drug therapy that is able to match each individual's chronobiology.

9.
Rom J Intern Med ; 52(4): 223-32, 2014.
Article in English | MEDLINE | ID: mdl-25726624

ABSTRACT

Cancer is the second cause of mortality worldwide, after cardiovascular diseases. Increased prevalence of cancer but also the fact that, most often, the diagnosis is established at a moment when therapeutic resources are already limited, constituted the premise for researching and developing indicators of disease or evolution. With the present article we aim to perform a brief review of the biomarkers currently in use in clinical practice for the diagnosis, prognosis and therapy of neoplasms, as well as those that are under evaluation.


Subject(s)
Biomarkers, Tumor , Neoplasms/diagnosis , Humans , Prognosis
SELECTION OF CITATIONS
SEARCH DETAIL
...